References
- Haldar P, Brightling CE, Hargadon B et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med.360, 973–984 (2009).
- Eder W, Ege MJ, von Mutius E. The asthma epidemic. N. Engl. J. Med.355, 2226–2235 (2006).
- Smith DH, Malone DC, Lawon KA, Okamoto LJ, Battista C, Saunders WB. A national estimate of the economic costs of asthma. Am. J. Respir. Crit. Care Med.156, 787–793 (20097).
- No authors listed. Proceedings of the ATS Workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. Am. J. Respir. Crit. Care Med.162, 2341–2351 (2000).
- Fahy JV. Eosinophilic and neutrophilic inflammation in asthma: insights from clinical studies. Proc. Am. Thorac. Soc.6, 256–259 (2009).
- Bousquet J, Chanez P, Lacoste JY et al. Eosinophilic inflammation in asthma. N. Engl. J. Med.323, 1033–1039 (20090).
- Woodruff PG, Khashayar R, Lazarus SC et al. Relationship between airway inflammation, hyperresponsiveness, and obstruction in asthma. J. Allergy Clin. Immunol.108, 753–758 (2001).
- Jatakanon A, Lim S, Barnes PJ. Changes in sputum eosinophils predict loss of asthma control. Am. J. Respir. Crit. Care Med.161, 64–72 (2000).
- Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. N. Engl. J. Med.346, 1699–1705 (2002).
- Akbari O, Faul JL, Hoyte EG et al. CD4+ invariant T-cell receptor + natural killer T cells in bronchial asthma. N. Engl. J. Med.354, 1117–1129 (2006).
- Pelaia G, Renda T, Romeo P, Busceti MT, Maselli R. Omalizumab in the treatment of severe asthma: efficacy and current problems. Ther. Adv. Respir. Dis.2, 409–421 (2008).
- Flood-Page P, Swenson C, Faiferman I et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am. J. Respir. Crit. Care Med.176, 1062–1071 (2007).
- Leckie MJ, ten Brinke A, Khan J et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet356, 2144–2148 (2000).
- Nair P, Pizzichini MM, Kjarsgaard M et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N. Engl. J. Med.360, 985–993 (2009).
- Wenzel SE, Schwartz LB, Langmack EL et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am. J. Respir. Crit. Care Med.160, 1001–1008 (1999).
- Lima JJ, Blake KV, Tantisira KG, Weiss ST. Pharmacogenetics of asthma. Curr. Opin. Pulm. Med.15, 57–62 (2009).
- Warrier MR, Hershey GK. Asthma genetics: personalizing medicine. J. Asthma45, 257–264 (2008).
- Cheong HS, Kim LH, Park BL et al. Association analysis of interleukin 5 receptor a subunit (IL5RA) polymorphism and asthma. J. Hum. Genet.50, 628–634 (2005).